Montelukast Should Not Be Used to Treat Bronchitis
Montelukast is not indicated for the treatment of bronchitis, whether acute or chronic, and there is no evidence supporting its use for this condition. The available evidence addresses only asthma, allergic rhinitis, and exercise-induced bronchoconstriction—not bronchitis.
Evidence-Based Treatment for Bronchitis
The ACCP evidence-based guidelines 1 provide comprehensive recommendations for chronic bronchitis management, and montelukast is notably absent from all treatment algorithms:
For Stable Chronic Bronchitis:
- First-line bronchodilators: Short-acting β-agonists (Grade A recommendation) 1
- Ipratropium bromide: Improves cough (Grade A recommendation) 1
- Theophylline: Consider for chronic cough with careful monitoring (Grade A recommendation) 1
- Combined therapy: Long-acting β-agonist plus inhaled corticosteroid for cough control (Grade A recommendation) 1
- Inhaled corticosteroids: For FEV1 <50% predicted or frequent exacerbations (Grade A recommendation) 1
For Acute Exacerbations of Chronic Bronchitis:
- Bronchodilators: Short-acting β-agonists or anticholinergics (Grade A recommendation) 1
- Antibiotics: Recommended, especially for severe exacerbations (Grade A recommendation) 1
- Systemic corticosteroids: 10-15 day course (Grade A recommendation) 1
For Acute Bronchitis:
- β-agonists: Not routinely recommended (Grade D recommendation) 2
- Antitussives: Codeine or dextromethorphan for short-term symptomatic relief (Grade C recommendation) 2
Why Montelukast Is Not Appropriate
The FDA-approved indications for montelukast 3 are limited to:
- Asthma (chronic treatment and prevention)
- Seasonal and perennial allergic rhinitis
- Exercise-induced bronchoconstriction
Bronchitis is fundamentally different from asthma. While both involve airway inflammation, chronic bronchitis is characterized by mucus hypersecretion and chronic productive cough without the reversible airflow obstruction and leukotriene-driven inflammation central to asthma pathophysiology 1.
Research Context
The available research on montelukast addresses only:
- Nonasthmatic eosinophilic bronchitis (NAEB)—a distinct condition from typical chronic bronchitis 4, 5
- Bronchiolitis obliterans syndrome after transplantation 6
- Asthma with cold-induced hyperactivity 7
None of these conditions are equivalent to acute or chronic bronchitis as clinically defined.
Clinical Bottom Line
If a patient presents with bronchitis:
- Chronic bronchitis: Use bronchodilators (β-agonists, ipratropium), consider inhaled corticosteroids if severe airflow obstruction, and ensure smoking cessation (Grade A recommendation) 1
- Acute bronchitis: Supportive care, consider short-term antitussives for troublesome cough 2
- Do not prescribe montelukast—it lacks evidence, indication, and mechanistic rationale for bronchitis treatment
The only scenario where montelukast might be considered is if the patient has concurrent asthma requiring treatment, but this would be treating the asthma, not the bronchitis.